A New Combination Treatment for Big Pharma GlaxoSmithKline?

By Max Macaluso and Dave Williamson – Sep 18, 2013 at 2:23PM

NYSE: GSK

GSK

Market Cap

$82B

Today's Change

(2.11%) $0.84

Current Price

$40.59

Price as of April 22, 2024, 4:00 p.m. ET

Glaxo's melanoma cocktail gets priority review from Food and Drug Administration.

Pharmaceutical company GlaxoSmithKline (GSK 2.11%) recently gained approval for two cancer drugs --- Mekinist and Tafinlar --- but the Food and Drug Administration recently announced that a combination treatment consisting of these two drugs has been given priority review status. In the following video from The Motley Fool's show Market Checkup, health-care analysts David Williamson and Max Macaluso discuss the details behind this news and the potential impact on GlaxoSmithKline's business.

The relevant video segment can be found between 3:25-6:01.

David Williamson has no position in any stocks mentioned. Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.